The company has a proprietary drug discovery platform based on the A3 adenosine receptor (A3AR). This receptor is highly expressed in inflammatory and cancerous cells but has low expression in normal cells, making it a promising target for developing drugs with fewer side effects. Can-Fite’s platform has enabled the company to develop multiple drug candidates, including Namodenoson (CF102), which is being tested for liver cancer and non-alcoholic steatohepatitis (NASH). This platform technology gives Can-Fite a unique edge in the development of targeted therapies for difficult-to-treat diseases.